Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL16666803 | 0.98 | TDP1 (0.50) | TDP1CYP1A2KMT2AKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL7476884 | 0.98 | TDP1 (0.50) | TDP1CYP1A2KMT2AKDM4EMEN1 | |
| SCHEMBL28552926 | 0.92 | TDP1 (0.45) | TDP1CYP1A2KMT2AKDM4EMEN1 | |
| SCHEMBL27155224 | 0.87 | ALDH1A1 (0.62) | TDP1KMT2AKDM4EMEN1USP2 | |
| SCHEMBL8149192 | 0.87 | ALDH1A1 (0.62) | TDP1KMT2AKDM4EMEN1USP2 | |
| SCHEMBL4498918 | 0.81 | TDP1 (0.52) | TDP1CYP1A2KMT2AKDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL27088452 | 0.80 | KMT2A (0.75) | TDP1CYP1A2KMT2AKDM4EMEN1 | |
| SCHEMBL21765685 | 0.80 | ALDH1A1 (0.54) | TDP1KMT2AKDM4EMEN1USP2 | |
| SCHEMBL802314 | 0.78 | CYP1A2 (0.54) | TDP1CYP1A2KMT2AALDH1A1LMNA | |
| SCHEMBL799201 | 0.78 | TDP1 (0.54) | TDP1CYP1A2KMT2AHTR1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712414-B2 | Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2023-08-01 | — | — | US | disclosed |
| CN-105142637-B | Oral pharmaceutical composition for preventing or treating dry eye comprising rebamipide or a prodrug thereof | 三进制药株式会社 | 2021-08-17 | — | — | CN | disclosed |
| CN-107438593-B | Therapeutic compounds and uses thereof | 基因泰克公司 | 2020-10-30 | — | — | CN | disclosed |
| EP-2987491-B1 | ORALLY ADMINISTRABLE PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DRY EYE SYNDROME, COMPRISING REBAMIPIDE OR PRODRUG THEREOF | SAMJIN PHARM CO LTD (KR) | 2020-06-03 | — | — | EP | disclosed |
| CN-110698491-A | 2- (camptothecin-10-oxyl) acetamide compound and application thereof | 西安交通大学 | 2020-01-17 | — | — | CN | disclosed |
| US-10301253-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301253-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| EP-3250552-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3250552-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-2105146-A1 | Nucleic-acid triggered release of molecules | Riken (JP) | 2009-09-30 | — | — | EP | disclosed |
| US-20090227691-A1 | METHOD FOR RELEASING MOLECULE OF INTEREST BASED ON TARGET NUCLEIC ACID SEQUENCE | RIKEN (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227691-A1 | METHOD FOR RELEASING MOLECULE OF INTEREST BASED ON TARGET NUCLEIC ACID SEQUENCE | RIKEN (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-0233461-B2 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-0233461-B1 | 4,5,6-Substituted-2-pyrimidinamines | AMERICAN CYANAMID CO (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0111281-B1 | NEW CEPHEM COMPOUNDS AND PROCESSES FOR PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-06-06 | — | — | EP | disclosed |
| US-4876252-A | ADMINISTERING ANTIASTHMATIC OR ANTIALLERGEN | AMERICAN CYANAMID COMPANY (US) | 1989-10-24 | — | — | US | disclosed |
| US-4788195-A | TREATING ASTHMA, ALLERGIC DISEASES, INFLAMMATION AND DIABETES IN MAMMALS | AMERICAN CYANAMID COMPANY (US) | 1988-11-29 | — | — | US | disclosed |
| US-4719206-A | ANTIBIOTICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-01-12 | — | — | US | disclosed |
| US-4584290-A | MICROBIOCIDES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009735-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KDM1B, HDAC1, DOT1L | TDP1 777/4885CYP1A2 1381/4885KMT2A 37/4885 |
| US-20090227691-A1 | METHOD FOR RELEASING MOLECULE OF INTEREST BASED ON TARGET NUCLEIC ACID SEQUENCE | DUT, ADAR, RNGTT | TDP1 139/4885CYP1A2 3792/4885KMT2A 2859/4885 |
| US-10301253-B2 | Therapeutic compounds and uses thereof | KDM1B, HDAC1, DOT1L | TDP1 777/4885CYP1A2 1381/4885KMT2A 37/4885 |
| US-11712414-B2 | Oral pharmaceutical composition for preventing or treating dry eye syndrome comprising rebamipide or a prodrug thereof | SI, PDE6D, PDE6H | TDP1 1090/4885CYP1A2 1033/4885KMT2A 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.